Anixa Biosciences and Cleveland Clinic Presented Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine
On Nov. 8, 2024, Anixa Biosciences announced updated positive data from the Phase 1 clinical trial of its…
On Nov. 8, 2024, Anixa Biosciences announced updated positive data from the Phase 1 clinical trial of its…
On Oct. 1, 2024, the American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update…
On Sept. 24, 2024, researchers at the National Institutes of Health (NIH) reported results of a study that…
On Sept. 18, 2024, researchers from the Wellcome Sanger Institute and their collaborators reported that they had identified…
On Sept. 3, 2024, a major study led by the UC Davis Comprehensive Cancer Center (UC DAVIS) has…
On Sep. 3, 2024, the National Cancer Institute (NCI) announced that the latest Cancer Trends Progress Report included…
On Jul. 31, 2024, a large study led by researchers at the American Cancer Society (ACS) suggested incidence…
On Jun. 26. 2024, the World Health Organization reported that new data show that nearly one third (31%)…
On May 15, 2024, the American Association for Cancer Research (AACR) released its biennial Cancer Disparities Progress Report…
On Apr. 30, 2024, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its…
On Aug. 31, 2023, the U.S. Food and Drug Administration (FDA) cleared for marketing the updated 23andMe Personal…
On May 9, 2023, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
On Mar. 9, 2023, the U.S. Food and Drug Administration (FDA) announced that it had published updates to…
On Feb. 3, 2023, the World Health Organization (WHO) released an updated Global Breast Cancer Initiative (GBCI) Framework…
On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Daiichi Sankyo’s Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV…
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
On Oct. 26, 2021, Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it had commenced…
On Nov. 13, 2020, Agilent Technologies announced it had received U.S. Food and Drug Administration (FDA) approval for…
On Nov. 13, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s…
On Jan. 11, 2016, the U.S. Preventive Services Task Force (USPSTF) recommended biennial screening mammography for women aged…
On Jun. 8, 2012, the U.S. Food and Drug Administration (FDA) announced that Genentech’s drug Perjeta (pertuzumab) was…
On May. 13, 2008, the Breast Cancer and Environmental Research Act of 2007 amended the Public Health Service…
In 2008, the Seattle Cancer Care Alliance introduced the Mammovan, making digital mammography more accessible to women throughout…
On Dec. 12, 2007, the Breast Cancer Research Stamp Reauthorization Act extended through Dec. 31, 2011, provisions requiring…
On Apr. 20, 2007, the National Breast and Cervical Cancer Early Detection Program Reauthorization Act of 2007 allowed…
On Mar. 28, 2007, Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one…
On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…
On Nov. 11, 2005, the U.S. Congress authorized the 2-year extension of Postage Stamp for Breast Cancer Research…